© Reuters Pfizer vs. Novavax: Which Vaccine Stock is a Better Buy?
As a large percentage of the population in the U.S has gotten vaccinated, some investors may be wary to hold onto vaccine stocks. But that may not be the case as different variants are popping up likely creating the need for booster shots. This benefits companies such as Pfizer (NYSE:) or Novavax (NASDAQ:). But which is a better buy? Read more to find out.Vaccine stocks are still worthy of close analysis in spite of the fact that the coronavirus pandemic is gradually reaching its end. Variants of the virus are popping up around the world. There is always a chance that the virus will continue to morph for months, years, or even decades, necessitating booster vaccine shots.
The companies that make coronavirus vaccines and booster vaccine shots have the potential to make a considerable amount of money while keeping the virus contained. These companies also have additional revenue drivers in the form of other vaccines. The question is which specific vaccine stocks are the best plays.
Sort through the entirety of the stocks that make vaccines, and you will find two, in particular, are especially intriguing. Below, we provide a look at whether Pfizer (PFE) or Novavax (NVAX) is the better play moving forward.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.